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Abstract.  Three forms of calpactin,  the 36,000 Mr 
Ca~-binding  cytoskeletal protein,  were isolated in 
large amounts  from bovine lung and human placenta 
using cycles of calcium-dependent  precipitation  fol- 
lowed by solubilization  with EGTA-containing  buffers. 
Calpactin-I  as a tetramer  of heavy (36 kD) and light 
(11 kD) chains  was the predominant  form of calpactin 
isolated,  however milligram  amounts of the calpactin-I 
heavy chain  monomer  and calpactin-II,  a  related but 
distinct  molecule,  were also isolated by this method. 
Calpactin-II  was characterized  in some detail and 
found to bind two Ca  ++ ions with K~'s of 10 I~M in the 
presence  of phosphatidylserine.  Both calpactin-I  and 
-II were found to aggregate liposomes at micromolar 
Ca  ++ concentrations,  suggesting that at least two 
phospholipid-binding  sites are present on these 
molecules.  Both calpactin monomers bind to and bun- 
dle actin filament at high  (1  mM) but not low (<1  laM) 
Ca  ~  concentrations.  Amino-terminal  sequence analysis 
of a  lower molecular mass variant  of calpactin-U re- 
vealed that this protein  was the previously  identified 
human "lipocortin" molecule.  Antibodies were elicited 
to calpactin-I  and -II and the cell and  subcellular dis- 
tribution  of each was compared.  Calpactin-II  was only 
present at high levels in tissues  (lung,  placenta)  which 
contained high levels of calpactin-I.  Other tissues  (in- 
testine)  contained  high calpactin-I  and undetectable 
levels of calpactin-II.  Double-label  immunofluores- 
cence microscopy on human  fibroblasts revealed that, 
like calpactin-I,  calpactin-II  is present in a  submem- 
braneous  reticular  network,  although  the distribution 
of the two calpactins  is not identical. 
T 
IlE  molecules  which  participate  in  connecting  the 
plasma  membrane  to the microfilament  system have 
remained rather elusive due to the complexity of the 
cortical cytoplasm in nucleated cells (16, 41).  One protein 
which has been suggested to be involved in membrane-to- 
filament linkage is spectrin,  the major membrane-skeletal 
protein of the erythrocyte (3, 33). A variant of spectrin has 
also been found in non-erythroid  cells where  it has been 
localized to a reticular network just under the membrane (2, 
30).  Although  additional  erythrocyte  membrane  skeletal 
proteins have been identified in other cell types (1, 5, 9, 34, 
35, 50), the mechanism and components involved in such a 
subcortical network need not be identical in all cells. 
The various functions of the microfilament systems appear 
to be governed by the actin-binding proteins in a given cell 
or subcellular compartment  (51, 54).  The observation that 
actin-binding  proteins are present in only a limited region 
of the  total  cellular  actin  distribution  is  consistent  with 
microfilaments  being involved in a  variety of functions as 
governed  by  the  associated  proteins.  Antibodies  to  non- 
erythroid spectrin have allowed a glimpse of a distinct actin 
organization in the cortical cytoplasm (2, 26, 30, 47). More 
recently, another actin-binding protein, 36,000 Mr, has been 
identified which also appears to be localized to the cytoskele- 
ton (4) in a similar distribution as spectrin (6, 36, 44). This 
protein, termed"calpactin" (also referred to as p36, p34, p39, 
or protein I) is a major substrate of the oncogene or growth 
factor receptor-associated protein tyrosine kinases (12,  13, 
39). Calpactin isolated from mammalian  intestine (18, 28), 
lymphocytes (8), or chick fibroblasts (14) is a complex of two 
distinct  subunits  with  molecular  masses  of 38,500  (heavy 
chain) and 11,000 (light chain) as estimated by amino acid se- 
quence. The light chain is related by amino acid sequence to the 
Ca++-binding  S-100 proteins of brain (20, 28, 37). The cal- 
pactin  light  chain  has  apparently  lost  the  ability  to  bind 
Ca  ++  (20,  23),  and  instead  the  Ca÷+-binding  sites  of cal- 
pactin-I have been assigned to the heavy chain subunit (19, 
23). The affinity of calpactin for Ca  ++ can be modulated by 
phospholipids (21, 23) with two Ca++-binding  sites detected 
for each calpactin heavy chain (Kd =  5 ~tM) in the presence 
of phosphatidylserine  (23). 
The domains of calpactin have been analyzed in some de- 
tail.  Chymotrypsin cleaves the calpactin-I heavy chain (36 
kD) into  COOH-terminal  core (33 kD) and NH2-terminal 
tail (3 kD) domains (28,  42). The core has been shown to 
contain all of the Ca  ++- and phospholipid-binding  activity 
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interaction with the calpactin light chain (29, 42) in addition 
to the sites of phosphorylation by pp60  s~ (31) and protein 
kinase C (32). 
Recently, a 36-kD substrate of the epidermal growth factor 
receptor tyrosine kinase has been detected in human A431 
cells (15, 49). This molecule, which has been termed p35 or 
calpactin-II,  shares  a  number  of structural  features  with 
calpactin-I and, using an assay based on the ability to interact 
with actin and phospholipid, appears to share these activities 
as well (22). Unlike calpactin-I, however, calpactin-II is only 
found as a monomer (15, 22), whereas calpactin-I can be de- 
tected as a monomer or complex with light chain (14, 19, 22). 
We now report the isolation of the calpactin-I complex, 
calpactin-I monomer, and calpactin-II from bovine lung and 
human placenta. We show that (a) calpactin-II is identical to 
lipocortin I;  (b)  calpactin-II binds 2  mol of Ca  ++ per mol 
protein, phospholipid dependently; (c) both calpactins bind 
to and bundle actin filaments at high Ca  ++ concentrations; 
and (d) there are significant differences in the tissue and sub- 
cellular distributions of calpactin-I and -II. 
Materials and Methods 
Purification of  Calpactins 
Frozen bovine lung (or fresh human placenta) is homogenized with a Waring 
blender in small aliquots (100 g) with an equal volume of 40 mM Tris,  1% 
Triton X-100, 10 mM EGTA, 2 mM MgC12, 0.5  mM dithiothreitol (DTT), 
0.2  mM  phenylmethylsulfonyl fluoride  (PMSF),  0.5  mM  benzamidine, 
pH 8.8. Homogenates were centrifuged 30 min at 15,000 g, and the superna- 
tant further centrifuged at 100,000 g  for 1 h. The soluble protein was ad- 
justed to  1 mM  free Ca  ++ (monitored with a  Ca++-selective  electrode), 
while maintaining the pH at 7.3-7.5  with 1 M Tris base. After stirring 20 
min at 4°C, precipitated protein was collected by centrifugation (100,000 g, 
1 h),  resuspended in  1(30 ml  10  mM imidazole, 2  mM MgCI2,  0.5  mM 
DTT, 2 mM CaCI2, pH 7.3, layered over 400 ml of 5% sucrose in the same 
solution, and centrifuged as above. The pellets were resuspended in 200 ml 
of 20 mM imidazole,  2 mM MgCI2, 0.5 mM DTT, 25 mM EGTA, 200 mM 
NaCI, pH 7.3, stirred 30 min at 4°C, and centrifuged at 120,000 g for 1 h. 
The supernatant was dialyzed overnight against 10 mM imidazole, 25 mM 
NaCI, 0.5  mM EGTA,  0.5  mM DTT, pH 7.3, and then adjusted to 1 mM 
free Ca  ++ as described above.  Precipitated protein was collected by cen- 
trifugation as before, resuspended in 15 m120 mM Tris,  1 M NaC1, 50 mM 
EGTA,  1 mM DTT,  2 mM MgCI2,  pH 8.0, and after stirring 30 min was 
centrifuged at 150,000 g for 1 h. The supernatant was applied to a 2.8-  × 
ll0-cm column of Sephacryl S-300 equilibrated and run in 20 mM NaPO4, 
0.5 M NaCI, 0.5 mM DTT, 20 mM EGTA, 2 mM MgCI2.  Fractions (6 ml) 
were collected and monitored by absorbance at 280 nm and every other frac- 
tion beginning at the void volume was analyzed by SDS PAGE. Peaks corre- 
sponding to the complex of calpactin-I with light chain (,'090,000  Mr) or 
the monomer peak ("~35-40 kD) were separately pooled, dialyzed against 
10 mM imidazole,  1 mM EGTA,  1 mM NAN3, 0.5 mM DTT,  pH 7.3, and 
applied to a 10-ml DE-52 column equilibrated in the same buffer. Calpactins 
flow through the DE-52 column unretarded and the other major proteins in 
the preparation, the 73-kD  protein (23) and the 32.5-kD protein (16) bound 
to the column and could be recovered by elution with salt. The calpactin 
pools were adjusted to 20 mM Na acetate, the pH adjusted to 5.6, and the 
solution was applied to a CM52 (Whatman Inc., Clifton, NJ) column and 
eluted with 1 M NaCI. This was used as the pure calpactin-I complex which 
was dialyzed against 0.5 mM DTT and stored as aliquots at -70°C. For the 
monomer fraction, the solution was dialyzed against  10 mM  imidazole, 
1 mM  NAN3, and  applied  to  a  3-ml  hydroxylapatite column  (Bio-Rad 
Laboratories, Richmond, CA) which was developed with a 0-200-mM lin- 
ear gradient of NaPO4,  pH 7.5. Fractions were monitored by absorbance at 
280 mM, SDS PAGE, Ca++-binding,  and Western blotting. The peak frac- 
tions corresponding to calpactin-II were pooled and dialyzed against 20 mM 
Na acetate, pH 5.6, applied to an FPLC mono-S-column (Pharmacia Fine 
Chemicals, Piscataway,  N J) which was eluted with a  150-400-mM  NaC1 
gradient. Calpactin-II was then dialyzed against 0.2 mM DTT and stored 
at 4°C. 
Liposome  Aggregation 
Fluorescently  loaded  liposomes were  prepared  by  drying  1  mg  phos- 
phatidylserine +  1 mg phosphatidylethanolamine together and sonicating 
into a  solution of rhodamine-conjugated IgG (Sigma Chemical Co.,  St. 
Louis, MO). The liposomes were separated from free rhodamine IgG using 
a  sucrose flotation gradient. The liposomes were then mixed with either 
BSA (control), calpactin-I, calpactin-I core, or calpactin-II in a  solution 
containing 10 mM imidazole, 40 mM KCI, 2 mM MgClz, 0.5 mM DTT, 
10 mM EGTA,  8.8 mM CaCI2 (10 mM free Ca++), pH 6.8. After 30 min, 
the liposome suspension was observed in a  Nikon optophot microscope 
equipped with epi-illumination. The interaction of  calpactin with liposomes 
was also monitored by light scattering as in reference 51 and low speed cen- 
trifugation  of 14C-PS-containing  liposomes as  follows.  Calpactins  were 
mixed with liposomes prepared as above (without fluorescent loading) in 
20 mM imidazole, pH 7.3, 150 mM KCI, 2 mM MgCI2,  1 mM CaC12, and 
allowed to sit at room temperature for 1 h. The absorbance at 320 nM was 
measured, and then the solution was centrifuged for 6  min at  13,000 g. 
Lipids in supernatant and pellet fractions were determined by scintillation 
counting of 14C-PS. 
Other Methods 
Two-dimensional gels of purified calpactins was performed with the non- 
equilibrium pH gradient electrophoresis (NEPHGE) first dimension (45) as 
described previously (22).  Peptide mapping of iodinated calpactin heavy 
Figure 1.  SDS  PAGE analysis of fractions at various stages in the 
purification of calpactin.  Frozen bovine  lung  tissue was  homog- 
enized in EGTA-containing buffer and after a high speed centrifuga- 
tion the extract (lane A)  was  adjusted to  1  mM  free Ca  ++  while 
maintaining the pH at 7.3.  The precipitate (lane B)  was collected 
by  centrifugation,  resuspended  in  buffer  containing  1  mM  free 
Ca  ++, and centrifuged through a 5 %  sucrose cushion. The pelleted 
material  (lane  C)  was resolubilized in  EGTA-containing  solution 
and  after  dialysis  followed  by  another  cycle  of  Ca++-induced 
precipitation, the protein soluble in  1 M  NaCI, 25 mM EGTA,  50 
mM  NaPO4  (lane D)  was  applied to  a  Sephacryi  S-200  column 
where a 90,000 Mr peak (E) and a 35,00040,000  Mr peak (lane F) 
were observed.  Peak fractions were pooled,  dialyzed against low 
salt buffer, and passed through a column of DEAE-cellulose. The 
peak of calpactin-I complex (lane G) was used as the pure protein 
whereas the monomer fraction (lane H) was further fractionated by 
hydroxylapatite chromatography  (see Fig.  2).  Additional  samples 
represent the calpactin-I complex (I and K)  and monomer (J and 
L) fractions from preparations of human placenta (1 and J) and bo- 
vine adrenal gland (K and L). Coomassie Blue-stained 12% acryl- 
amide SDS  gel. 
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Bovine Lung and Human Placenta 
Bovine lung  Human placenta 
Total protein Calpactin-I Total protein Calpactin-I 
mg  mg  mg  mg 
Extract  24,600  204  31,000  53 
First Ca  +÷ pellet  3,240  201  3,080  43 
Second Ca  ++ pellet  1,250  232  570  36 
EGTA soluble 
protein  780  230  304  48 
Third Ca  ++ pellet  440  195  96  34 
S-200 column starting 
solution  171  108  81  22 
Complex (90,000 
Mr) peak  83  60  31  11 
Monomer (36,000 
Mr) peak  27  12  19  7 
DEAE flow-through 
(complex)  45  45  9.6  9.6 
DEAE flow-through 
(monomer)  14  6.1  11  5 
The total protein  at each step was determined using the BCA protein assay 
(Pierce Chemical Co.) and the amount of calpactin was determined by Western 
blots using (a) anti-bovine intestinal calpactin-I and (b) comparison to known 
amounts of pure calpactin run in adjacent lanes of the same gel. 
and light chains was as described (22). Ca+÷-binding by equilibrium dialy- 
sis of calpactin-ll in the presence or absence of phospholipid was performed 
as described (23).  Actin-binding and -bundling was monitored as in refer- 
ence 31. Sequence  determination was performed as in reference  28. Anti- 
bodies were elicited in rabbits against bovine calpactin-II  (see Fig. 2, Peak 
A) which was further purified by reverse-phase  HPLC using a wide pore 
C-4 column (J. T. Baker Chemical Co., Philipsburg, NJ) and eluting with 
a  linear 40-60%  acetonitrile gradient in 0.1% trifluoroacetic  acid.  Peak 
fractions  were dried under vacuum, sonicated  in PBS, emulsified  with an 
equal  volume of Freund's  complete (first injection) or incomplete  (subse- 
quent injections)  adjuvant and 400 lag was injected subcutaneously  and in- 
tramuscularly.  Antibodies were purified from the serum by affinity chroma- 
tography using Peak A protein (see Fig. 2) coupled to Sepharose and elution 
from the column with 4 M MgCI2. Western blots were performed as de- 
scribed (25) using a 1:200 dilution of anti-p35 serum (see Fig. 2) (gener- 
ously provided by Stanley Cohen, Vanderbilt University, Nashville,  TN) or 
2 lag/ml affinity-purified anti-ealpactin-II (see Fig. 9). Double-label immu- 
nofluorescence  microscopy  on human fibroblasts  was performed on cells 
fixed for 2 h in 3.7% formaldehyde  and permeabilized with 0.2%  saponin 
in PBS containing 20 mM ethanolamine, pH 8.0. A mouse monoclonal anti- 
body to human calpactin-I (40) was provided by Dr. Claire Isacke (The Salk 
Institute)  and used at a  1:20 dilution of ascites  fluid. 
The calpactin-I  heavy chain, derived from the calpactin-I  complex was 
separated from the light chain by denaturation in 6 M guanidine,  gel filtra- 
tion on Sephacryl  s-300, and renaturation essentially  as described previ- 
ously (28). The core was purified from chymotryptic digests of calpactin-I 
as in reference 29. Protein determinations were made using the BCA assay 
(Pierce  Chemical Co.,  Rockford,  IL). 
Figure 2.  Fractionation of monomeric calpactins on hydroxylapatite. The calpactin monomer peak, after passing through a DEAE column 
in low salt,  was loaded onto a  hydroxylapatite column which was developed with a  linear 0-200 mM NaPO4  gradient.  Fractions were 
monitored for absorbance at 280 nm (solid line)  and selected fractions tested for Ca÷+-binding activity in the presence of 200 ~tg phos- 
phatidylserine per ml by equilibrium dialysis at  10 ~M free Ca  ++ (solid symbols).  The radioactivity bound represents cpm per  15 lal of 
the fraction above buffer where the buffer alone gave a value of 6,000 cpm. (Inset)  SDS PAGE and Western blot analysis of calpactin peaks 
from the hydroxylapatite column. Lanes A, B, and C represent pooled fractions corresponding to peaks A, B, and C. One set (1) was stained 
with Coomassie Blue while the other two were transferred to nitrocellulose and treated with antibodies to human calpactin-II from A431 
cells (2) or antibodies to bovine intestinal calpactin (3).  Blots were then treated with  125I-protein  A  and subjected to autoradiography. 
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mer fractions. Bovine lung (A, C, and E) or human placenta (B, 
D, and F) calpactin-I (C and D), calpactin-II (A and B), or a mix- 
ture of the two (E and F) were run on a non-equilibrium pH gra- 
dient electrophoretic (NEPHGE) separation system for separation 
by charge in the first dimension (migration from left to right, with 
the more basic component to the right) and size (SDS PAGE) in the 
second dimension (migration from top to bottom). For comparison, 
an extract of A431 cells either alone (G) or mixed with placental 
calpactin-II (H) were analyzed. Only the relevant portions of the 
Coomassie Blue-stained gels are shown. 
Results 
Purification and Characterization of Calpactins 
Previous methods for the purification of  calpactin-I as a com- 
plex of heavy and light chain subunits from mammalian tis- 
sue involved the preparation of microvillus vesicles in Ca  ++ 
and the elution of calpactin with EGTA (18, 27).  With the 
finding that a high degree of purity can be achieved by re- 
precipitating with Ca  ++ (24), we sought to exploit this ob- 
servation using other tissue sources.  As  shown in Fig.  1, 
cycles of Ca++-induced  precipitation followed by EGTA re- 
solubilization from an extract of lung  resulted in  the en- 
richment of polypeptides with molecular masses of 73,000, 
36,000, and 32,000. Gel filtration of this material in high salt, 
low  Ca++-containing  buffers  allowed  the  separation  of a 
high molecular mass material, which eluted at the void vol- 
ume,  from  the  other  polypeptides.  Of particular  interest 
were two peaks containing 36-kD proteins, one peak eluting 
at a position corresponding to a  native molecular mass of 
95,000 and the second at the 35,000--40,000-mol-wt  position. 
We used Western blotting to quantitate the amount of calpac- 
tin-I present at various stages in this procedure using an anti- 
body to intestinal calpactin-I (23). As shown in Table I, this 
procedure is quite selective for calpactin. Starting with 750 
g of tissue, we could isolate 45 mg of calpactin-I as a com- 
plex with light chain from bovine lung or 10 mg from human 
placenta (Table I). When the amount of total protein is com- 
pared to the amount of calpactin-I as determined with a West- 
ern blot, it is clear that the peak of calpactin eluting from 
the gel filtration column in the monomer position consisted 
of more than one component, even after ion exchange chro- 
matography  (Table I).  Fractionation of this  protein  on  a 
hydroxylapetite column revealed that  at  least three Ca++- 
binding components (labeledA, B, and C) were present (Fig. 
2). Since previous studies from this laboratory have shown 
that two distinct calpactins are detectable in cultured cells 
(22), we tested the three peaks for  Jmmunoreactivity with an- 
tibodies to calpactin-I and -II (also termed p35). As shown 
in the inset to Fig. 2, antibodies to calpactin-II react with dis- 
tinct molecular weight variants in all three peaks whereas 
anti-calpactin-I reactivity is largely confined to a 36-kD band 
in peak C.  A likely interpretation is that intact calpactin-II 
is represented in Peak A,  and slightly smaller variants of 
calpactin-II, due to proteolytic nicking, were separated into 
peaks B and C. A similar profile was observed with protein 
derived from human placenta (not shown). 
Single  Coomassie-stained  spots  were  observed  for the 
36-kD proteins from the hydroxylapatite column (Peaks A 
and  C)  of both  bovine  lung  and  human  placenta.  When 
mixed, the two spots (Peaks A and C) were clearly resolved, 
and the Peak A component from human placenta was found 
to exactly co-migrate with the previously identified calpac- 
tin-II spot (22) from A431 cells (Fig. 3 H). The calpactin-I 
monomer co-migrated with the heavy chain of  the calpactin-I 
complex in this gel system (not shown). 
Amino acid sequence analysis was performed on calpac- 
tin-II-related proteins (Fig. 4). Whereas the higher molecu- 
lar mass  form (Peak A,  Fig.  2) did not give rise to a  se- 
quence, indicating an apparently blocked amino terminus, a 
unique sequence of 28 residues was observed for the slightly 
lower molecular mass variant of bovine calpactin-II (Peak B, 
Fig. 2). Comparison of this sequence to the predicted struc- 
ture of the amino-terminal region of human lipocortin (53) 
revealed  that  25  of 28  residue  positions  were  identical, 
PEAK  A  NONE 
PEAKB  FIENEEQEY  IKTVKGSKGGPGSAVSPYP  .... 
III  III  II  I  I  I  I  )  I  I  II  I  III  IIII 
HUMAN  LIPOCORTIN  A  M  V  S  E  F  L  K  Q  A  W  F  I  E  N  E  E  Q  E  Y  V  Q  T  V  K  S  S  K  G  G  P  G  S  A  V  S  P  Y  P  T  F  N  ... 
Figure 4. Amino-acid sequence analysis of  the bovine calpactin-II derivatives (see Fig. 2). No sequence was observed for the highest molecu- 
lar mass form of calpactin-II (peak A) indicating a blocked amino terminus, whereas a sequence commencing with phenylalanine was 
observed for peak B (all sequences given in the single letter amino acid code). The bottom line represents the predicted amino-terminal 
sequence of human lipocortin (53) for comparison. Vertical lines indicate positions where the amino acid is identical between lipocortin 
and peak B protein. 
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Figure 5.  Effect of phospho- 
lipid  on  Ca++  binding  by 
calpactin-II.  Calpactin-II  in 
the  presence  (open squares) 
or  absence  (solid diamonds) 
of phosphatidylserine was sub- 
jected to equilibrium dialysis 
with  4sCaC12  at  increasing 
Ca  ++  levels.  After  dialysis, 
the  amount  of  Ca  ++  bound 
was  determined  by  scintilla- 
tion counting and the amount 
of protein  determined  using 
the Pierce BCA protein assay. 
B  is  the  scatchard  plot  of 
Ca++ binding  by  calpactin-II 
in  the  presence  of phospha- 
tidylserine. 
thereby indicating  that bovine calpactin-II and human lipo- 
cortin are equivalent  proteins. 
Ca ++ Binding 
Calpactin-I and its core have been shown to bind Ca  ++, with 
the binding greatly enhanced by phospholipid (23). To deter- 
mine whether calpactin-II has this activity, equilibrium dial- 
ysis was performed with 45Ca in the presence or absence of 
phospholipid.  In the absence of phospholipid,  Ca  ++ binding 
was barely detectable at the micromolar range of Ca  ++ (Fig. 
5 A). In the presence of phosphatidylserine,  by contrast, cal- 
pactin bound stochiometric amounts of Ca  ++ with two Ca  ++- 
binding  sites  detected  with  dissociation  constants  in  the 
100  ~1 
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0 
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Figure 6.  Liposome aggrega- 
tion  induced  by  calpactin-I 
and  Ca  ++.  Calpactin-I  (solid 
symbols)  or  the  calpactin-I 
core  (open symbols), which 
lacks the  amino-terminal tail 
and the light chain,  were in- 
cubated at the  specified con- 
centration  with  liposomes 
containing  '4C-phosphatidyl- 
serine / phosphatidylethanola- 
mine/cholesterol (1:1:1). After 
30  min,  light  scattering  was 
measured (absorbance at 320 
rim;  b). The tubes were then 
capped  and  centrifuged  at 
10,000 g for 5 min and the dis- 
tribution  of lipid  was  deter- 
mined by scintillation  count- 
ing  of supernatant  and pellet 
fractions (a). 
range of 10 gtM. Interestingly, Scatchard analysis revealed a 
curve rather than a  straight line which would be expected if 
the binding  is cooperative (Fig.  5  B).  Such a  phenomenon 
was not  seen with calpactin-I  (23). 
Phospholipid Aggregation by Calpactin 
Calpactins aggregate liposomes as detected by three indepen- 
dent methods.  First,  at increasing  calpactin concentrations, 
light  scattering  increased  (Fig.  6  A).  Second,  calpactin 
caused liposomes to form aggregates that were collected by 
low  speed centrifugation  (Fig.  6  B).  Third,  when  fluores- 
Figure 7.  Liposome aggregation as moni- 
tored  microscopically  using  rhodamine- 
loaded liposomes. Liposomes loaded with 
rhodamine-conjugated  IgG  were  mixed 
with 125 ~tg calpactin-I per ml (complex of 
heavy  and  light  chains)  (A),  with  the 
calpactin-I core (B), with calpactin-II (C), 
or with serum albumin (D).  After 30 min 
at room temperature, aggregates were visu- 
alized in the fluorescence microscope. All 
micrographs were taken at the same magni- 
fication with the  same exposure time and 
printed identically.  Bar,  40  p.m. 
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calpactin-II (b and c) were incuba~xl  with actin at high (a and b) 
or  low  (c)  Ca  ++  concentrations.  The  solution  was  applied  to  a 
carbon-coated grid, stained with 2% uranyl acetate, and observed 
in a Zeiss electron microscope operated at 80 kV. Bar, 0.9  ~tm. 
cently loaded liposomes were used, the aggregation could be 
detected in the fluorescent microscope (Fig. 7). Without cal- 
pactin  present  a  fluorescent  haze  was  observed  since  in- 
dividual  liposomes  are below the  level of detection  in the 
light  microscope.  Large  fluorescent  aggregates  were  the 
dominant  feature  of those  liposome preparations  to which 
calpactin was added.  Surprisingly, the core (which lacks the 
amino-terminal  tail  and  light  chain)  possessed  the  same 
lipid-aggregating activity as the calpactin complex as moni- 
tored by all  three assays (Figs.  6  and  7). 
Actin-binding and -bundling by Calpactins 
Since  the  calpactin-I  complex  has  been  shown  to  bind  to 
and bundle  actin filaments at high Ca  ++ (18, 27),  we tested 
Figure 9. Comparison of the tissue distribution of calpactin-I and 
-II. Human platelets  (d),  erythrocytes (e),  or placenta  (f),  and 
mouse  spleen  (g),  kidney  (i),  liver (j),  lung  (k),  intestine  (l), 
cardiac muscle (m), skeletal muscle (n), and brain (o), and rat adre- 
nal gland (h) were solubilized directly into SDS sample buffer. Pro- 
teins were resolved by SDS PAGE and transferred to nitrocellulose 
membrane.  Membranes  were  then  treated  with  antibodies  to 
calpactin-I  (upper gel) or  calpactin-II (lower gel) followed  by 
~25I-protein A  and autoradiography.  Standards  of calpactin-I (c), 
calpactin-II (see Fig. 2, peak A [a] and peak B [b]) were included 
in adjacent lanes of each gel. Only the relevant portion of each au- 
toradiograph is shown. 
whether calpactin-II and the calpactin-I core have the same 
effect. Both calpactin-I and -II and the calpactin-I core bind 
to actin filaments as judged by a cosedimentation assay (data 
not  shown).  Controls  showed  that in  the  absence  of Ca  ++  , 
calpactins were only found in the supernatant of a high speed 
centrifugation  assay,  whereas  with  actin present they were 
found  in  the  pellet.  Calpactin  also  bundles  actin  at  high 
Ca  ++ concentrations.  In the absence of calpactin,  only sin- 
gle actin filaments were observed, whereas large bundles of 
actin were found with either calpactin-II, calpactin-I, or the 
calpactin-I core  (Fig.  8). 
Both calpactin-I and -II have been found in three different 
cell lines. Thus, it becomes important to determine whether 
both  calpactins  are  present  together  in  all  situations  or 
whether they are independently expressed. To determine this 
distribution  we  used  Western  blots  of total  tissue  protein 
solubilized  directly  in  SDS  sample  buffer,  run  on  a  10% 
acrylamide gel and probed with anti-intestinal calpactin-I or 
anti-lung  calpactin  II.  As  shown  in  Fig.  9,  in  ceils  where 
calpactin-I is low or undetectable,  such as brain, liver, plate- 
lets and red cells, calpactin-II is also negligible.  Two tissues 
stand  out  as  high  in  calpactin-II;  placenta  and  lung,  and 
both tissues are rich in calpactin-I. In other tissues,  such as 
intestine, a high level of calpactin-I was observed with unde- 
tectable amounts of calpactin-II present.  Although an exten- 
sive tissue  survey  was  not performed,  we  found  no  situa- 
tion  where  there  was  high  calpactin-II  in  the  absence  of 
calpactin-I. 
Since many tissue culture cells are known to contain high 
levels of calpactin-I and -II, and calpactin-I is known to be 
just  under  the  membrane,  we analyzed  the  distribution  of 
calpactin-II in human fibroblasts by double-label  immuno- 
fluorescence  microscopy.  As shown in Fig.  10,  calpactin-II 
was found in a rather punctate distribution,  much more dis- 
crete than calpactin-I in the  same cells.  The pattern  of the 
two calpactins  was clearly similar and the distribution  was 
partially overlapping. This indicates that calpactin-II is in the 
same type of cortical  microfllament network. 
Discussion 
Calpactin  was  isolated  from bovine  lung  and  human  pla- 
centa. Typical yields of 30-60 mg of the calpactin-I complex 
The Journal of Cell Biology, Volume 104, 1987  508 Figure  10.  Double-label immunofluorescence microscopy of cal- 
pactin-I (A) and calpactin-II (B) in the same human fibroblast cell. 
Cells grown on coverslips were fixed in formaldehyde, permeabi- 
lized in saponin, and treated with a mouse monoclonal anti-cal- 
pactin-I antibody (A), plus rabbit anti-calpactin-II afffinity-purified 
antibodies (B). Reactivity was visualized with fluorescein-conju- 
gated sheep anti-mouse IgG plus rhodamine-conjugated goat anti- 
rabbit IgG antibodies and observed in the fluorescein (A) or rhoda- 
mine (B) channels. Bar, 20 Ixm. 
are the highest thus far reported and should allow a  more 
complete analysis of this molecule. In addition, calpactin-II, 
a related but distinct protein, and the calpactin-I monomer 
were isolated in  lesser amounts  as  a  by-product.  We had 
previously used a  similar type of procedure to isolate the 
calpactin-I complex from bovine intestine (23). In that prep- 
aration, the calpactin-I core was an abundant component of 
the  monomer  peak  of the  gel  filtration  separation  (23). 
There was no indication that calpactin-II was present in that 
fraction and indeed the present results (Fig. 9) indicate that 
very little calpactin-II is present in intestine. In lung, how- 
ever, the situation is different. The monomer peak yielded 
significant amounts of calpactin-II, fragments of calpactin-II 
gi ~o 
Calpactin-I complex 
i  ,prL 
~,lembr 3he 
Chymotrypsltl 
Calpactin-t  monomer 
Calpactin-il 
MembraPe 
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Figure 11. Membrane association of three forms of calpactin found 
in many cells. See Discussion for detail. 
(Fig. 2), and intact calpactin-I monomer, whereas little cal- 
pactin-I core was found. 
Fig.  11 is an attempt to summarize the following features 
of calpactins.  (a)  Three forms of calpactin have been de- 
scribed; the calpactin-I complex of heavy and light chains; 
the calpactin-I monomer, and calpactin-II. (b) The calpactin 
light chain,  which is homologous to S-100 (20,  31,  37),  is 
known to exist as a dimer (19). (c) The heavy chain of  calpac- 
tin-I can be envisioned as consisting of two distinct domains, 
a 33-kD core domain and a 3-kD tail which can be dissected 
by limited chymotryptic cleavage at residues 23 and 29 (28). 
(d)  Both calpactins  have two Ca++-binding  sites,  both of 
which have been localized to the core and are probably on 
opposite sides of the molecule. (e) Calpactins bind to phos- 
pholipids (21, 23,  42; see also Results), and phospholipids 
enhance the  affinity of calpactin  for  Ca  ++  (23).  (f)  The 
light chain interacts with the blocked amino-terminal tail of 
the calpactin-I heavy chain (29),  but not with calpactin-II 
(22).  (g)  The  site  of phosphorylation  by  the  oncogene 
pp60  src is known to reside in the tail (22). This model does 
not address the possibility of linkage to the cytoskeleton by 
actin or spectrin, nor does it incorporate potential phospholi- 
pase A2 inhibitory activity (43, 46, 48; see below). In addition, 
the interactions and structure are necessarily oversimplified. 
The  full  sequence  of both calpactin-I heavy chain  and 
lipocortin has recently been determined and compared (38, 
43, 48). The two proteins display approximately a 50% over- 
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served for both proteins in the previously recognized "core" 
region, which is known to bind Ca  ++ and phospholipid and 
this is connected to a 30-amino acid tail which represents the 
amino terminus of calpactins. The amino acid sequence ho- 
mology between lipocortin and the heavy chain of  calpactin-I 
is unequally distributed through the polypeptide with the 
highest degree found in the repeats within the core (43-70 % 
identity) and the least homology (15%) in the tail (43, 48). 
A detailed comparison of the functions of these proteins then 
should help us to understand the implications of this se- 
quence homology. 
The core domain of the calpactin-I heavy chain has been 
shown  previously  to  bind  Ca  *+  and  phospholipid,  with 
phospholipid able to  increase the affinity of calpactin for 
Ca  *+. In the presence of phosphatidylserine, each calpactin 
heavy chain monomer binds two Ca  ++ ions with a Kd of 4.5 
~tM. Although other proteins such as protein kinase C and 
the Ca+÷-activated  protease are  known to shift their Ca  +÷ 
sensitivity in response to phospholipids, direct Ca+÷-bind  - 
ing measurements for this class of proteins has only been 
reported for calpactin-I. We now show that each calpactin-II 
molecule also binds 2 mol of Ca  ++ per mol, also dependent 
on  phospholipid.  Interestingly,  the  affinity  for  Ca  +÷  is 
slightly  lower  (Kd  =  10  IxM) for  calpactin-II  than  for 
calpactin-I, and the binding appears  cooperative (Fig.  5). 
These features should be kept in mind when attempting to 
assign  the  Ca+÷-binding  site to  particular  regions  of the 
calpactin-I and -II sequence. 
Calpactins bind to and aggregate phospholipids. This was 
found using a low speed centrifugation assay, light scattering 
(Fig.  6),  and  microscopic  visualization of fluorochrome 
trapped in liposomes (Fig. 7). This aggregation phenomenon 
is probably related to the Ca  +÷ binding which is greatly en- 
hanced by phospholipids. Thus, we suggest that a ternary 
complex of calpactin,  Ca  ++,  and phospholipid is  formed, 
with these sites found on opposite sides of each core domain 
(Fig.  11). If the two Ca  ++ and phospholipid sites were on 
the same side of the molecule, for instance, one might expect 
lipid binding but not aggregation or cross-linking. In this re- 
spect, calpactin-I and -II display an activity similar to syn- 
exin (7) or calelectrin (17, 52). In those cases, however, vesicle 
aggregation  required  millimolar  concentrations  of  Ca  ÷+, 
whereas it is found at 10 IxM Ca  +÷ with calpactins (Fig. 7). 
Another difference is  that aggregation with calpactin was 
measured using pure lipid rather than membrane vesicles. 
Previous studies have shown that the calpactin-I complex 
binds  to,  and bundles  actin  filaments in  the  presence  of 
Ca  ++ (18, 27). In the present study,  we find that the calpac- 
tin-I core and calpactin-II also bundle actin filaments. The 
simplest model of a bundling protein is one which has two 
actin-binding sites and forms cross-linkages between paral- 
lel-oriented actin filaments at regular intervals (11). The fact 
that the calpactin core has this effect would suggest that two 
actin-binding sites are found on each heavy chain subunit. 
Thus, the fourfold repeat structure may also include two or 
more actin-binding sites in addition to two Ca++/phospho - 
lipid sites. 
Calpactin-I has been previously shown to have the proper- 
ties of a cytoskeletal protein (4) and immunofluorescence mi- 
croscopy has demonstrated that it is present in a submem- 
braneous distribution similar to spectrin. The list of proteins 
which  are  present  in  this  network  includes  erythrocyte 
cytoskeletal proteins (see above) and a 73-kD protein which 
co-purifies with calpactin-I through much of the procedure 
(24) and is probably the 68-kD protein which has been iso- 
lated from porcine lymphocytes (8).  We can now include 
calpactin-II  in  this cytoskeletal network.  Immunottuores- 
cence microscopy reveals that the two calpactins have a very 
similar, although not identical, distribution. The distribution 
of calpactin-II appears more punctate although the nature of 
these fluorescent dots is not known. It is possible that this 
corresponds to some type of small vesicle population in the 
cell. Future experiments will explore this possibility. 
After this work was completed, a report by De et al. ap- 
peared concerning the isolation of a 35-kD substrate for the 
epidermal growth factor receptor kinase from porcine lung 
(10). According to the amino acid sequence which was pre- 
sented, they have isolated the truncated form of calpactin-II 
(peak B of Fig. 2; see Fig. 4) and shown that tyrosine 20 is 
phosphorylated by the epidermal growth factor receptor. The 
results on the tissue distribution of p35 in adult tissues is in 
substantial agreement with the data presented herein (e.g., 
high in lung and placenta and low in liver and intestine). In 
that study they suggested that calpactin-II (p35) binds Ca  ++. 
This  is  now  confirmed by  direct  Ca++-binding  measure- 
ments in the presence or absence of phospholipids (Fig. 5). 
Lipocortin has been characterized as an extracellular pro- 
tein which inhibits pancreatic phospholipase A2. Although 
both calpactins have an identical phospholipase inhibitory 
activity (Davidson, E  E, E. A. Dennis, M. A. Powell, and 
J. R. Glenney, Jr., J. Biol. Chem., in press) this is due to their 
effect  on  phospholipids  rather  than  the  enzyme  itself. 
Regardless  of the  mechanism,  the  question  arises  as  to 
whether the major biological function of calpactin is the in- 
hibition of intracellular phospholipase A2.  Given that cal- 
pactins are major cellular proteins, and are cytoskeletal pro- 
teins that directly interact with the lipid bilayer, we prefer 
the  idea  that they  are  membrane-to-cytoskeleton linkage 
molecules. The availability of a method for the large-scale 
purification of these proteins should allow rapid progress in 
answering these questions. 
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